Patents by Inventor Paul J. Hoogestraat

Paul J. Hoogestraat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aldosterone synthase inhibitor
    Patent number: 8778984
    Abstract: The present invention provides aldosterone synthase inhibitors of the formula: intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: July 15, 2014
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Paul J. Hoogestraat, Thomas Edward Mabry, Quanrong Shen, Ana Maria Escribano
  • Aldosterone Synthase Inhibitor
    Publication number: 20120322841
    Abstract: The present invention provides aldosterone synthase inhibitors of the formula: intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 20, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Michael Gregory Bell, Paul J. Hoogestraat, Thomas Edward Mabry, Quanrong Shen, Ana Maria Escribano
  • CB1 modulator compounds
    Patent number: 7595339
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: September 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
  • CB1 MODULATOR COMPOUNDS
    Publication number: 20080287504
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
    Type: Application
    Filed: August 17, 2007
    Publication date: November 20, 2008
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, JR., Daryl Lynn Smith
  • CB1 antagonist compounds
    Patent number: 7276516
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Steven Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith